may decrease alcohol intake and reduce motivation to consume alcohol.
Preclinical studies indicate that GLP-1 receptor agonists can prevent relapse drinking.
Human studies confirm that GLP-1 receptor agonists reduce alcohol intake in patients with .
Genetic variations in the GLP-1 receptor are associated with alcohol use disorder and heavy drinking.
The mechanisms through which GLP-1 affects alcohol-related behaviors may involve reward-processing areas in the brain.
Simplified
Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addiction. Specifically, preclinical studies demonstrated that GLP-1 receptor agonists decrease alcohol intake, reduce the motivation to consume alcohol, and prevent relapse drinking by potentially lowering alcohol-induced reward. These preclinical results have been confirmed and extended in human studies in which GLP-1 receptor agonists reduce alcohol intake in patients with (AUD) who have a regular weight or comorbidity of obesity or type 2 diabetes. On a similar note, genetic variations in genes encoding for the GLP-1 receptor are associated with AUD and heavy drinking. The central mechanisms by which GLP-1 regulates alcohol-related behaviors are not fully defined, but may involve areas central to reward as well as regions projecting to these reward areas, such as the nucleus tractus solitarius of the brainstem. Together, existing preclinical and clinical data suggest that GLP-1 is involved in the AUD process and implies its role as a tentative treatment for AUD.
Key numbers
12 weeks
Reduction in alcohol intake
Duration of dulaglutide treatment reducing alcohol intake in patients with .
2 separate population cohorts
Genetic association
Population cohorts showing SNP associations with diagnosis.
Full Text
We can’t show the full text here under this license.
